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Abstract
Gaucher disease is characterized by lysosomal accumulation of glucosylceramide due to
deficient activity of lysosomal glucocerebrosidase (GBA). In cells, glucosylceramide is also
degraded outside lysosomes by the enzyme glucosylceramidase 2 (GBA2) of which inherited
deficiency is associated with ataxias. The interest in GBA and glucosylceramide metabolism
in the brain has grown following the notion that mutations in the GBA gene impose a risk factor
for motor disorders such as α-synucleinopathies. We earlier developed a β-glucopyranosyl-
configured cyclophellitol-epoxide type activity based probe (ABP) allowing in vivo and in vitro
visualization of active molecules of GBA with high spatial resolution. Labeling occurs through
covalent linkage of the ABP to the catalytic nucleophile residue in the enzyme pocket. Here,
we describe a method to visualize active GBAmolecules in rat brain slices using in vivo label-
ing. Brain areas related to motor control, like the basal ganglia and motor related structures in
the brainstem, show a high content of active GBA. We also developed a β-glucopyranosyl
cyclophellitol-aziridine ABP allowing in situ labeling of GBA2. Labeled GBA2 in brain areas
can be identified and quantified upon gel electrophoresis. The distribution of active GBA2
markedly differs from that of GBA, being highest in the cerebellar cortex. The histological find-
ings with ABP labeling were confirmed by biochemical analysis of isolated brain areas. In con-
clusion, ABPs offer sensitive tools to visualize active GBA and to study the distribution of
GBA2 in the brain and thus may find application to establish the role of these enzymes in
neurodegenerative disease conditions such as α-synucleinopathies and cerebellar ataxia.
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Introduction
Gaucher disease (GD) is caused by a recessively inherited deficiency of the lysosomal hydrolase
glucocerebrosidase (GBA) encoded by the GBA gene. The enzyme deficiency results in lyso-
somal accumulation of its glycosphingolipid substrate, glucosylceramide (GlcCer) [1]. In con-
trast to other, more complex glycosphingolipids and galactosylceramide, GlcCer is present
both in the cytosolic and luminal leaflets of membranes. Degradation of GlcCer in cells is there-
fore not restricted to the lysosomes, but also partly takes place through the action of the non-
lysosomal β-glucosylceramidase 2 (GBA2) [2]. GD patients generally show a massive GlcCer
accumulation in lysosomes of tissue macrophages in the spleen, liver and bone marrow, leading
to characteristic hepatosplenomegaly, thrombocytopenia, anemia and leukopenia. Prominent
pathology of the central nervous system does not develop in most GD patients. This non-neu-
ropathic variant is commonly referred to as type 1 GD. More severely affected GD patients, so-
called type 2 and 3 GD, do present neurological symptoms stemming from neuronal degenera-
tion [1]. Postmortem evaluations of brain from GDmice and type 2 and 3 GD patients have
revealed α-synuclein (Lewy body) deposits in brainstem and midbrain structures like the pyra-
midal tracts and the pontine nucleus (Po), the basal ganglia (striatum, substantia nigra (SN),
globus pallidus (GP)), the subthalamic nucleus, the cerebellum and the hypothalamus [3,4].
Neuronal loss in type 2 and 3 GD patients is most evident in the cortex and in dopaminergic
neurons of the SN [4]. Of note, GD patients, and even carriers of mutations in the GBA gene,
are at increased risk for developing motor disorders such as Parkinsonism [5–10]. Likewise, in
mice reduced GBA activity leads to accumulation of α-synuclein species [11, 12]. In mouse
models of GD and Parkinson disease, introduction of active GBA in the brain by lentiviral gene
therapy has a beneficial effect [13, 14]. The lysosomal integral membrane protein type-2
(LIMP-2) mediates the transport of newly formed GBA to lysosomes [15]. Brain of LIMP-2–
deficient mice with reduced GBA activity shows increased α-synuclein deposits causing neuro-
toxicity of dopaminergic neurons as well as apoptotic cell death and inflammation [16]. At
present, therapeutic introduction of GBA, or LIMP-2, in the brain is still not feasible. Current
enzyme replacement therapy (ERT) of GD patients is based on two-weekly intravenous infu-
sions with macrophage-targeted recombinant glucocerebrosidase [17]. Although ERT results
in improvements in the viscera, neurological manifestations in type 2 and 3 GD patients are
not prevented by the intravenous enzyme infusions. This lack of effect is ascribed to the poor
passage of ERT enzyme across the blood brain barrier. An alternative approach for modulating
GlcCer metabolism in the brain may be offered by the use of brain-permeable small com-
pounds inhibiting GlcCer synthase [18]. The presently registered inhibitors for substrate
reduction therapy of GD do not prevent neurological manifestations due to poor brain perme-
ability [19]. Development of better brain-permeable inhibitors of GlcCer synthase would be
therefore required for this and is actively pursued [20].
Given the importance of abnormalities in GBA for neurological manifestations in type 2
and 3 GD patients, as well as its possible role in onset of α-synucleinopathies, far more detailed
information of localization of active GBA in the brain is desired. The same holds for the
enzyme GBA2. In recent years, we developed a new toolbox to study active GBA and GBA2
molecules within living cells and laboratory animals. Detection is based on β-glucopyranosyl-
configured cyclophellitol-type ABPs that specifically and covalently link to the catalytic nucleo-
phile in the enzymatic pocket of retaining β-glucosidases, employing the double-displacement
mechanism for catalysis. The developed ABPs are equipped with a green- or red fluorescent
BODIPY group and allow ultrasensitive visualization of the active enzyme molecules in vitro
and in vivo [21–26]. The first class of ABPs consists of compounds with a cyclophellitol β-
epoxide moiety linked to a fluorescent BODIPY group [20, 24]. Covalent binding to the
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catalytic glutamate 340 of GBA proceeds by the same mechanism as that of conduritol B-epox-
ide (CBE) [20, 24]. The cyclophellitol β-epoxide type ABPs with distinct fluorescent BODIPY
moieties specifically label active GBA molecules, and are for convenience here referred to as
inhibodies. The second class of ABPs consists of β-aziridine cyclophellitol with a linked fluores-
cent BODIDY group. Contrary to the cyclophellitol β-epoxide ABPs, the β-aziridine cyclophel-
litol-type structures label the entire class of retaining β-glucosidases, including GBA, GBA2,
GBA3, and lactase/phoridzin hydrolase (LPH) [23, 27]. This broad-specific ABP is here
referred to as Anybody. A drawback of all BODIPY-containing ABPs is their inability to pene-
trate the brain [21]. Following intravenous or intraperitoneal administration of ABPs the target
enzymes (GBA and/or GBA2) are efficiently labeled in all tissues with exception of the eye and
brain [21–23, 28].
The primary objective of this study was to establish whether intracerebroventricular (i.c.v.)
infusion of cyclophellitol β-epoxide ABPs offers a suitable method to specifically visualize in
vivo active GBA molecules with high spatial resolution. The secondary objective was to study
the feasibility of labeling active GBA2 in the intact brain by i.c.v. infusion of the β-aziridine
cyclophellitol ABP. We here describe the outcome of the investigation and discuss the observed
distribution of active GBA and GBA2 molecules in rat brain.
Materials & Methods
Materials
The various ABPs (cyclophellitol β-epoxide MDW933 (Inhibody Green); cyclophellitol β-
epoxide MDW941 (Inhibody Red); β-aziridine cyclophellitol MDW1044 (Anybody Green); β-
aziridine cyclophellitol JJB75 (Anybody Red)) were synthesized exactly as described earlier [21,
23]; conduritol B-epoxide (CBE) was purchased from Sigma (St Louis, USA).
Animals
Wistar rats (20 male individuals, 8–10 weeks old) were used for i.c.v. administration of ABPs.
For each ABP administration group, 4 animals were used. Each animal was kept in an individ-
ual cage at constant temperature (23°C ± 2°C), submitted to a 12/12h light/dark cycle. They
were exposed to ad libitum food and water before and after the experimental procedures. All
animal protocols were approved by the Institutional Animal Welfare Committee of the Aca-
demic Medical Center at the University of Amsterdam, Amsterdam (The Netherlands).
Methods
In vivo i.c.v. administration of fluorescent ABPs to the brain. Wistar rats were infused i.
c.v. with fluorescent ABPs. Animals were anesthetized with a mixture of 0.4 ml/kg Dormicum
(Roche, Almere, The Netherlands) and 0.8 ml/kg Hypnorm (Janssen, High Wycombe, Buck-
inghamshire, UK). Intracerebroventricular stainless steel guide cannulas were implanted in the
lateral ventricle using the following stereotaxic coordinates: AP -0.9, L +2.0 and V -3.4, tooth
bar (-.2.5mm). Analgesic Buprecare (Recipharm, Lancashire, UK) was administered after the
animals woke up from the surgery. After a recovery period of 7 days (body weight recovery to
the pre-surgery point), a needle connected to a tube was introduced in the guide cannula and
PBS solutions containing 1 mM of different ABPs (MDW933 and MDW941) were infused
with a rate of 1 μl/min for 10 minutes. After 4 hours, the animals were sacrificed by CO2 eutha-
nasia and transcardially perfused with 250 ml of 0.9% (w/v) saline solution. In indicated experi-
ments, animals were first i.c.v. infused with CBE (1 mM in PBS) at 1 μl/min for 10 minutes.
After 4 hours of recovery, the animals received i.c.v. Anybody Red (JJB75) at the same
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concentration and rate as above. After another 4 hours, the animals were sacrificed by CO2
euthanasia and transcardially perfused with 250 ml 0.9% (w/v) saline solution. Brains were iso-
lated and immediately frozen for further biochemical and histological analysis.
Analysis of brain sections. Rat brains were cut in 30 μm slices with a cryostat and
attached to SuperFrost slides (Thermo Scientific, Waltham, USA). All following steps were in
the dark to protect the fluorescence of the ABPs. Slides were extensively washed in 0.01 M
Tris-buffered saline (TBS) to remove non-specific fluorescence and were covered in DAPI
(Vector Lab, Burlingame, USA) mounting media.
For immunohistological analysis, brain slices were extensively washed in TBS, next incu-
bated overnight in TBS containing 0.5% (v/v) Triton X-100, 0.025% (v/v) gelatin and supple-
mented with one of the following primary antibodies (1:1000): rabbit anti-rat LAMP1
(Millipore, MA, USA), Cathepsin D (Millipore, MA, USA), NeuN (Millipore, MA, USA),
GFAP (DAKO, Heverlee, Belgium), Cd11b (Sigma, St Louis, USA), Iba1 (Wako, California,
USA), GBA (Sigma, St Louis, USA), Calbindin D 28 K (Millipore, MA, USA) and GBA2 (see
description below). Hereafter, slides were incubated with appropriate secondary antibodies
(1:1000) conjugated with fluorescent dyes; either donkey anti-rabbit Alexa488 or Alexa647
(Life Technologies, Paisley, UK) for 2 hours. After rinsing slides three times in TBS, these were
mounted and covered with DAPI to be observed in a confocal laser-scanning microscope
(Leica SP5). The rabbit polyclonal anti-mouse GBA2 antibodies were generated using the Dou-
ble XP program from Eurogentec (Liege, Belgium), with the GBA2 peptides CGSPEDSGPQD
EPSY and GRYYNYDSSSHPQSR. Final bleeds were affinity purified using the same peptides.
For the isolation of rat brain areas, frozen brains were dissected in 10 areas. The cerebellum,
brainstem and spinal cord were isolated from the rest of the brain by separating the hindbrain
from the cortical lobes at the level of inferior colliculus. The pons was separated and the brain-
stem cut slightly lower of the obex to separate it from the spinal cord. For the hippocampus,
small curved blunt forceps were introduced between the cerebral hemispheres in a closed posi-
tion, slowly opening the forceps; the cortex was separated from the hippocampus. The hippo-
campus was next dissected. For the dissection of the cerebellum, slices of 300 μmwere made
from the whole cerebellum and with a steel needle the area of the cerebellar cortex was taken
per slice. The rest of the cerebellum from each slice was considered cerebellum. For the cingular
cortex, putamen and globus pallidus, slices of 300 μm from the enlargement of the lateral ven-
tricle and beginning of the putamen were made. Using a steel needle, the cingular cortex 1 and
2 and the anterior putamen alone were dissected, and subsequently the putamen and globus
pallidus. Before hypothalamus dissection, the frontal part of the brain was cut coronally for dis-
section of the forebrain areas. After that, blunt curved forceps were introduced at the level of
the mammillary nucleus and the hypothalamus was separated from the rest of the brain.
Finally, the thalamus was dissected above the border of the missing hypothalamus and the
anterior commissure using a steel needle.
Analysis of ABP labeling by gel electrophoresis and fluorescence scanning. Lysates of
rat dissected brain areas were made by homogenizing the frozen material in 25 mM potassium
phosphate buffer, pH 6.5, supplemented with 0.1% (v/v) Triton X-100 and protease inhibitor
cocktail (Roche, Indianapolis, USA). The electrophoresis in sodium dodecyl sulfate containing
7.5% polyacrylamide gels and quantitative scanning of the gels was exactly performed as earlier
described [21, 23]. Protein was determined using the Pierce BCA Protein Assay kit (Thermo
Scientific, Paisley, UK).
Enzymatic activity assays. For determination of GBA-associated β-glucosidase activity,
3.75 mM 4-methylumbelliferyl-β-D-glucopyranoside (Sigma, St Louis, USA) was used as artifi-
cial substrate at 37°C, in 150 mM citric acid-Na2HPO4 at pH 5.2, in the presence of 0.2% (w/v)
sodium taurocholate, 0.1% (v/v) Triton X-100 and 0.1% (w/v) bovine serum albumin (BSA)
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[29]. Determination of GBA2-associated β-glucosidase activity occurred in 150 mM citric acid-
Na2HPO4 at pH 5.8 in the presence of the same substrate and 0.1% (w/v) BSA [2]. β-Hexosa-
minidase activity was measured with 1.97 mM 4-MU-N-acety-β-D-glucosaminide in 150 mM
citric acid-Na2HPO4, pH 4.0, supplemented with 0.1% (w/v) BSA. All enzymatic reactions
were stopped with excess NaOH-glycine (pH 10.6) and fluorescence of liberated 4-methylum-
belliferone was measured with a fluorimeter LS55 (Perkin Elmer) using λex 366 nm and λem
445 nm.
Isolation of microglia and astrocytes. Wistar rats were anesthetized and perfused with
Hank’s Balanced Salt Solution (HBSS) from Life Technologies (Carlsbad, USA). Their brains
were dissected in forebrain and hindbrain (brainstem, spinal cord and midbrain including sub-
stantia nigra) and kept in ice-cold HBSS. After the isolation of the brain, the hindbrain was cut
at the level of the inferior colliculus and an extra slice was made with a steel blade to also obtain
the substantia nigra. After mechanical homogenization using a steel blade, the tissue was
digested with papain (Worthington, Lakewood, USA) at a final concentration of 8 U/ml with
DNAse I at 80 units/μl (Sigma, St Louis, USA). The mixture was centrifuged at 200× g for 15
minutes and the pellet was triturated to obtain a single cell suspension. Myelin was removed by
a 90% Percoll demyelination and a FACS sorting procedure, using myelin removal beads (Mil-
tenylBiotec, Bergisch Gladbach, Germany). For a detailed description of the isolation proce-
dure see Orre et al [30].
For the sorting by FACS cells were incubated with a custom-made anti-rabbit polyclonal
GLT1 antibody (Biomatik, Wilmington, USA) (1:100), a rabbit anti-rat Cd11b-APC antibody
(eBioscience, San Diego, USA) (1:200) and an Fc-receptor blocker CD32 (BD Pharmigen, San
Diego, USA) for 30 minutes. After washing of cells, these were incubated with a biotinylated
antibody (Jackson Immunoresearch, Suffolk, UK). After additional washings, cells were again
incubated with streptavidin APC-Cy7 (Biolegend, San Diego, USA) and next resuspended in
GKN/BSA buffer (8 g/L NaCl, 0.4 g/L KCl, 1.77 g/L Na2HPO4•2H2O, 0.69 g/L NaH2PO4•H2O,
2 g/l D-(1)-glucose, pH 7.4). To differentiate viable from dead cells, 7AAD (BD Bioscience, San
Diego, USA) was added. Cells were sorted using a BD FACS After gating the dead cells based
on 7AAD expression, astrocytes were sorted based on GLT1+/CD11b- expression, microglia
were sorted based on CD11b+ expression and the rest of the cells were sorted as non-GLT1
+/CD11b+ cells. The sorted cells were lysed immediately after and either used for RNA extrac-
tion or cells were frozen as a dry pellet for subsequent labelling with ABP.
RNA extraction and RT PCR. The sorted cells were lysed and total RNA was extracted
using a Nucleospin II extraction kit (Macherey-Nagel GmbH, Duren, Germany). cDNA was
synthesized according to the Invitrogen cDNA synthesis kit. Gene expression analysis was per-
formed using a Bio Rad MyIQ Real Time PCR detection system. The expression levels were
normalized to P0 and GADPH expression levels. For the confirmation of the cell types, we
used the primers presented in Table 1.
ABP labeling of enzymes in isolated astrocytes and microglia. To label GBA in the
astrocytes and microglia, cell pellets were incubated with 200 nMMDW933 (Inhibody green)
in McIlvaine buffer (150 mM citric acid-Na2HPO4, pH 5.2, 0.2% (w/v) sodium taurocholate,
0.1% (v/v) Triton X-100) with protease inhibitors (Roche Diagnostics Ltd, Indianapolis, USA)
for 30 min at 37°C. Samples were denatured with Laemmli loading buffer (1 M Tris-HCl, pH
6.8, 0.1% (w/v) bromophenol blue, 60% (w/v) glycerol, 100 mM DTT) and boiled for 4 min at
100°C. SDS-PAGE (electrophoresis in sodium dodecylsulfate (SDS) 7.5% polyacrylamide gels)
was performed and followed by fluorescence scanning as earlier described [21].
Western Blot Analysis. Rat brain area homogenates (100μg) were subjected to electropho-
resis on 7.5% SDS-polyacrylamide gels and then transferred to nitrocellulose membranes
(Whatman, Dassel, Germany) using an electroblotting apparatus (Bio-Rad Laboratories,
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Hercules, CA). The blots were blocked in 2% (w/v) non-fat dried milk in TBST buffer (10 mM
Tris-HCl, pH 8.0, 150 mMNaCl, 0.05% (v/v) Tween-20) and incubated with α-GBA (Sigma,
St. Louis, USA), α-GBA2 (Eurogentec custom made) and α-Tubulin (Cedarlane Laboratories,
Ontario, Canada) primary antibodies diluted in blocking buffer, overnight at 4°C. Blots were
washed for 30 minutes in TBST. After washing, the membranes were incubated with matching
IRDye-conjugated secondary antibodies (Westburg BV, Leusden, Netherlands) for 1 hour at
room temperature. Blots were scanned on an Odyssey image scanner (GE Healthcare).
Confocal image analysis. Images were made with a Confocal SP5 Leica, using an excita-
tion wavelength of 488 nM for Alexa488 and MDW933, 561 nM for Alexa594, MDW941 and
JJB75, and 652 nM for Alexa647. A 63× objective was used for image capture, and a further 3×
zoom was used for single-cell images.
Live imaging of brain tissue ex vivo. Seven male C57BL/6J mice were anesthetized in an
isofluorane chamber and once they were unconscious, decapitation was performed. Their
brains were isolated and briefly perfused with ice-cold sucrose cutting solution (72 mM
sucrose, 22 mM glucose, 2.6 mM NaHCO3, 83 mM NaCl, 2.5 mM KCl, 3.3 mMMgSO4 mM
and 2 mM CaCl2). Directly after, the brain was placed in a vibratome (Thermo scientific,
Microm HM 650V) in the aforementioned sucrose solution and gassed with 5% CO2 / 95% O2.
Coronal brain slices of 400 μm thick were made of the midbrain, from in front and behind the
substantia nigra, and next transferred to a water bath at 37°C in artificial CSF (118 mMNaCl,
2.5 mM KCl, 26 mM NaHCO3, 1 mM NaH2PO4, 10 mM glucose, 4 mMMgCl2, 4 mM CaCl2,
Table 1. Primers used for RT PCR of mRNA of specific genes expressed in astrocytes andmicroglia.
Astrocytes markers
Glial high affinity glutamate transporter, member 2 (Slc1a2) FWD: 5'-agtgtgtctatgccgcacac-3'
REV: 5'-ggctgagaatcgggtcatta-3'
Aldehyde dehydrogenase 1 family, member L1 (Aldh1l1) FWD: 5'-gcaccttttggaggattcaa-3'
REV: 5'-ggcaacagggtacaggagaa-3'
Fibroblast growth factor receptor 3 (Fgfr3) FWD: 5'-cgttgtagagagggctggac-3'
REV: 5'-gaggcttgccacataagagc-3'
Microglia markers
Allograft inflammatory factor 1 (Aif1) FWD: 5'-aatgatgctgggcaagagat-3'
REV: 5'-cctccaattagggcaactca-3'
Integrin, alpha M (Itgam) FWD: 5'-cgtttgtgaaggctcagaca-3'
REV: 5'-gtcgtttgaaaaagccaagc-3'
Integrin, beta 2 (Itgb2) FWD: 5'-agtcccagtggaacaacgac-3'
REV: 5'-ggaggggtctcctctgactc-3'
Chemokine (C-X3-C motif) receptor 1 (Cx3cr1) FWD: 5'-gcctcaacccctttatctacg-3'
REV: 5'-tgctcctctgggactctgtt-3'
Oligodendrocytes markers
Myelin basic protein (Mbp) FWD: 5'-ccgaggagagtgtgggttta-3'
REV: 5'-ctggagggtttgtttctgga-3'
Myelin-associated oligodendrocyte basic protein (Mobp) FWD: 5'-caggaccacacgatttctt-3'
REV: 5'-ggaggtcagagcacaagagg-3'
Neuronal markers
Syntaxin 1A (Stx1a) FWD: 5'-gctctgaaaagccaggtgtc-3'
REV: 5'-cagctggctgctgaatactg-3'
Neurofilament, medium polypeptide (Nefm) FWD: 5'-agtggtggtgaccaagaagg-3'
REV: 5'-caccagcttctcctcaaagg-3'
doi:10.1371/journal.pone.0138107.t001
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pH 7.4, gassed with 5% CO2 / 95% O2) for 30 minutes. Next, the slices were transferred to a
petri dish in a chamber for live-cell imaging with 5% CO2 / 95% O2 and a constant temperature
of 37°C. Slices were fixed using a tissue adhesive (3M, Vetbond, Minnesota, USA) in one corner
of the slice away from the substantia nigra area. Subsequently, a drop of DAPI mounting
media was added to be able to visualize the cells using a 40× magnitude objective in a Zeiss
Axiovert 200 M fluorescence microscope. Twenty-second interval time-lapse images were
made as a basal measurement for 10 minutes. Next, the slices were incubated with 5 nM
MDW941 (Inhibody red) and immediately time-lapse imaging was again resumed. Next, the
media were removed and slices were directly frozen for further histological analysis. In some
experiments, additional slices were first incubated with CBE (650 μM) for 60 minutes prior to
time-lapse imaging as described above.
After the time-lapse imaging, mouse brain slices (30 μm) were stained with primary rabbit
anti-mouse antibody against tyrosine hydroxylase (TH) (Abcam, Cambridge, UK). Washings
and secondary antibody staining was performed as described above.
Histochemical detection of GBA2 in Purkinje cells of mouse brain. Mice were anaesthe-
tized using FFMmix (hypnorm/dormicum/distilled water, 1:1:2 volume). Brains were dis-
sected. Formalin-fixed, paraffin-embedded tissue was sectioned at 4-μm thickness, dried
overnight at 37°C, deparaffinized in xylene and rehydrated in graded alcohol. Endogenous per-
oxidase activity was blocked by incubation for 10 min in methanol containing 0.3% H2O2. Sec-
tions were rehydrated and slides were heated in 0.04 M citrate, 0.12 M phosphate, pH 5.8, for
10 min at 121°C. After washing, the sections were incubated with primary antibody being
either polyclonal rabbit IgG anti-mouse GBA2 or rabbit IgG anti-calbindin D-28K (PC253L,
1:1,000; Calbiochem, San Diego, CA, USA), in Antibody Diluent (ImmunoLogic, Klinipath,
Duiven, The Netherlands) for 16 hours at 4°C, washed, and incubated with secondary anti-
body. Sections were counterstained with methyl green and mounted with VectaMount (Vector
Laboratories). Analysis was performed using brightfield microscopy (Leica DM5000B) with an
HC PLAN APO 20x/0.70 objective.
Statistical analysis. The FACS sorted population experiments were analyzed by two-way
ANOVA, followed by the Bonferroni post-hoc test. For the gene-expression of isolated cells,
one-way ANOVA was performed, followed by the Tukey post-hoc test. For both tests, a proba-
bility of p<0.05 was set as significant. The data was analyzed using a SPSS version 15 statistical
package.
Results
Visualization of active GBA by i.c.v. administration of with cyclophellitol
β-epoxide MDW933
To fluorescently label active GBA molecules in the brain, in vivo i.c.v. infusions with cyclophel-
litol β-epoxide ABPs were performed in living rats. Firstly, we infused Wistar rats i.c.v. with
green fluorescent MDW933 (Inhibody green) for 10 minutes. Four hours after the infusion,
animals were sacrificed, their brain was collected, sliced, and the presence of ABP signal was
studied by fluorescence microscopy (Fig 1). GBA antigen in slices was also visualized by immu-
nohistochemistry with anti-GBA antiserum. The fluorescent ABP showed a lysosomal signal
that almost completely overlapped with GBA antigen staining (Fig 1a and 3x zoom 1b). Immu-
nohistochemical staining of lysosomal LAMP1 (Fig 1c) revealed that the ABP signal is largely
localized in lysosomes.
We next identified areas of rat brain with high and low concentrations of GBA molecules as
labeled with cyclophellitol-epoxide type ABPs MDW933 (Inhibody green) or MDW941 (Inhi-
body red). With both ABPs similar results were obtained. Fig 2a shows that motor related areas
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such as basal ganglia (GP and SN), the medial geniculate nucleus (MGN) and brainstem motor
related structures such as the spinal trigeminal nucleus (SP5), lateral reticular nucleus (Lrt) and
Po contain relative high concentrations of active GBA molecules compared to other structures.
Motivational and memory related brain areas appear to contain relatively lower concentrations
of active GBA molecules, particularly the hippocampal CA1, CA2, and CA3, the dorsal subicu-
lum and the habenular nucleus (Fig 2b). It should be mentioned that the hippocampus is
known to express high P-glycoprotein activity (see for an example [31]). BODIPY-containing
compounds, like the ABPs used, are known to act as substrates for P-gycoprotein mediated
Fig 1. Cyclophellitol-epoxide ABPMDW933 administered i.c.v. labels specifically lysosomal GBA in the brain. (A) 63x Confocal images showing from
left to right: DAPI stain, MDW933 (green Inhibody) labeling, GBA antibody labeling (red) and their overlay in the Po of the brainstem. (B) Zoom (3x) 63x
confocal images showing clear colocalization. (C) Zoom (3x) 63x confocal images showing from left to right: DAPI stain, green MDW933, the lysosomal
protein LAMP1 antibody labeling (red) and their overlay in the Po of the brainstem.
doi:10.1371/journal.pone.0138107.g001
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efflux from the brain. Therefore it is possible that the relatively modest labeling of GBA in the
hippocampus is due to low local ABP concentrations.
Next, punches of specific brain areas of two untreated rats were isolated and homogenates
thereof were incubated with 100 nM green fluorescent Inhibody MDW933. Labeled GBA was
visualized by SDS-PAGE gel electrophoresis and fluorescence scanning, while applying per
Fig 2. Prominent GBA-labeling by infused inhibody ABPs in motor related areas of the brain. (A) Strong red MDW941 labeling of brainstemmotor
related structures Po, SP5, Lrt, SN and MGN after i.c.v. administration. Example of green MDW933 labeling of GP (middle panel left). (B) Modest labeling of
motivational and memory processing areas. Example of modest MDW933 labeling of hippocampus (left panel) and modest MDW941 labeling of dorsal
subiculum, and habenular (middle and right panel).
doi:10.1371/journal.pone.0138107.g002
Active Glucocerebrosidase in Rodent Brain
PLOS ONE | DOI:10.1371/journal.pone.0138107 September 29, 2015 9 / 20
lane identical amounts of total protein. As shown in Fig 3a and 3b, the hypothalamus and the
cingulate cortex seem to contain relatively high amounts of active GBA molecules per total pro-
tein as determined with the BCA assay. Similar results were obtained with materials of two
rats. The brainstem, thalamus, basal ganglia and hippocampus appear to contain slightly
smaller amounts of active GBA per total protein. Next, we determined the enzymatic activity of
GBA per total protein in the same punches (Fig 3c). A similar pattern for active GBA was
noted by ABP labeling and measurement of enzyme activity. It should be pointed out that relat-
ing ABP labeling (or enzymatic activity) to total protein as determined by the Pierce BCA assay
is to some extent misleading. Comparing ABP labeled GBA with Coomassie Brilliant Blue
stained protein in the same fraction (see Fig 3a) suggests that the differences in GBA level
between regions are relatively small.
Additional Western blot analysis of GBA antigen showed that the same brain areas contain
similar GBA protein levels, except for the Globus pallidus + Putamen, which seem to show less
GBA protein content (Fig 3d and 3e).
To confirm specific GBA labeling in brain, we also performed ex vivo time-lapse analysis of
the SN of mice (Fig 4). Time-lapse imaging of slices incubated with red fluorescent Inhibody
MDW941 (5 nM) alone showed perinuclear labeling typical for lysosomes (Fig 4b). Slices incu-
bated with cerebral spine fluid (CSF) as control lacked this signal (Fig 4a). Pre-incubation of
slices with CBE, a known irreversible inhibitor of GBA, blocked fluorescent labeling with
MDW941 [15], thus prevented labeling of any lysosomal structures (Fig 4c). Tyrosine hydroxy-
lase positive dopaminergic neurons showed high amounts of active GBA labeling (Fig 4d).
Dopaminergic neurons in the SN are involved in the output of motor movement and coordina-
tion and are affected in α-synucleinopathies like Parkinson disease (PD) [19].
To investigate more closely which cell types of the brain present low and high amounts of
active GBA molecules, we stained brain sections from Inhibody MDW933-infused rats for dif-
ferent markers of microglia (Cd11b and Iba1), astrocytes (GFAP) and neurons (NeuN). Histo-
logical analysis of basal ganglia and brainstem motor related structures revealed that active
GBA is abundantly present in neurons marked by presence of NeuN (Fig 5a and 5e). Active
GBA is also present in astrocytes and microglia. In the astrocyte-rich median eminence (ME),
GFAP positive cells were labeled by ABPMDW933, although less prominently than NeuN pos-
itive cells (Fig 5b and 5e). The same was observed for the microglia (CD11b positive and Iba1
positive) in different motor areas like the SN (Fig 5c, 5d and 5e).
Next, microglia and astrocytes were isolated from forebrain (hippocampus, anterior basal
ganglia and cortex), and hindbrain (combined midbrain and brainstem areas) from rats. Astro-
cytes were purified by FACS sorting based on GLT1, a glutamate transporter expressed specifi-
cally in astrocytes widely throughout the brain. Microglia cells were sorted based on CD11b
expression. Due to the high autofluorescence of microglia, a special gating of the 7AAD posi-
tive signal for the microglia populations was used [30]. The FACS procedure gave clear separa-
tion of the GLT1 positive/CD11b negative population (astrocytes) and the CD11b positive
population (microglia). We performed RT PCR for astrocyte markers in the GLT1 and CD11b
positive populations. The GLT1 positive cell population showed a higher mRNA expression of
genes prominently expressed in astrocytes: Slc1a2, Aldh1l1, Aqp4 and Fgfr3, and low or no
mRNA expression of genes prominently expressed in microglia: Aif1, Itgam, Itgb2 and Cx3cr1
(Fig 6a and 6b). CD11b positive cell populations showed a high mRNA expression of genes
mostly expressed in microglia: Aif1, Itgam, Itgam and Cxc3r1, especially of Cxc3r1 being the
highest expressed in CD11b positive cell populations (Fig 6a and 6b). To additionally confirm
the purity of the astrocyte and microglia populations, we analyzed the mRNA expression of
genes that are mostly expressed in neuronal cells and oligodendrocytes. Both GLT1 and
CD11b positive populations showed no mRNA expression of genes expressed in neurons
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(Stx1a and Nefm) and no mRNA expression of genes expressed in oligodendrocytes (Mbp and
Mobp) (Fig 6a and 6b). GBA in sorted astrocyte and microglia cell population was labeled with
200 nMMDW933. Astrocytes were found to contain more active GBA per cell compared to
microglia cells (p<0.003) (Fig 6c).
Labeling of active GBA2 with aziridine-cyclophellitol ABP
We next employed the β-aziridine cyclophellitol ABP which broadly target β-glucosidases [23].
It was first examined whether brain GBA2 can be labeled with these Anybody ABPs. For this
purpose, we incubated punches of specific brain areas of untreated rats in vitro with 100 nM
green fluorescent Anybody MDW1044 (Fig 7). Following gel electrophoresis and fluorescence
scanning, three distinct proteins become visible: GBA2 with MW ~100 kDa, GBA with MW
~60 kDa and a protein of about 40 kDa.
Fig 3. Active GBA in specific brain areas. (A) SDS-PAGE gel of Inhibody MDW933 labeled rat brains areas. The asterisk indicates positive control
recombinant GBA signal. As a loading control the same gel was stained with Coomassie brilliant blue (CBB). (B) Quantification of fluorescence expressed
per μg of total protein. (C) Enzymatic activity of GBA in brain areas, as determined with 4MU-β-d-glucopyranoside substrate. (D) GBA protein levels in
homogenates of rat brain areas assessed byWestern blot analysis. (E) Quantification of GBA blot in rat brain areas normalized to tubulin.
doi:10.1371/journal.pone.0138107.g003
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Fig 4. Ex vivo live imaging of GBA labeling in the SN. (A) Ex vivo live imaging of DAPI-stained SN during 10 minutes with a 20 second interval per picture.
(B) Ex vivo live imaging of the SN after 5 nMMDW941 administration to the media. (C) Ex vivo live imaging of the SN after incubation with CBE followed by
Inhibody addition to the media. (D) TH antibody staining of SN slices after ABP labeling.
doi:10.1371/journal.pone.0138107.g004
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Fig 5. Presence of active GBA in neurons. Shown is zooming (3×) of 63× confocal images in A-C. (A) SN of i.c.v. infused rats with MDW933. From left to
right images of DAPI, green MDW933, red NeuN antibody staining and overlay image. The overlay shows the Inhibody label around NeuN positive nuclei of
neuronal cell suggesting lysosomal localization. (B) Median Eminence (ME) of i.c.v. infused rats with MDW933. From left to right images of DAPI, green
MDW933, red GFAP antibody and overlay image. The overlay shows GFAP positive cells with concomitant Inhibody labeling. (C) SN of i.c.v. infused rats
with MDW933. From left to right images of DAPI, green MDW933, red CD11b antibody and overlay image. The overlay shows MDW933 signal in areas
Active Glucocerebrosidase in Rodent Brain
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The enzyme GBA2 was detected in all regions (Fig 7a and 7b). A similar result was obtained
by measuring GBA2 activity in homogenates of the punches (Fig 7c). The cerebellar cortex
showed the highest amount of active GBA2 with both methods. Similar findings were made by
Western blot analysis of GBA2 antigen, in which the cerebellar cortex and hypothalamus
showed higher levels of GBA2 (Fig 7d and 7e).
To study more closely other enzymes in the cerebellar cortex than GBA being labeled by
Anybody ABP, we first blocked GBA for Anybody labeling by prior i.c.v. infusion with Inhi-
body or CBE. Rat brains were i.c.v. infused with green fluorescent Inhibody MDW933 followed
by red Anybody JJB75 or the combination CBE followed by JJB75. Microscopic analysis of the
cerebellar cortex from rats sequentially infused with green Inhibody MDW933 followed by red
Anybody JJB75 showed both green and red fluorescence within the same neuronal cells (Fig
8a). The distribution of red Anybody labeling was similar in brains of animals firstly infused
with CBE (Fig 8b). We noted prominent red Anybody labeling in the cerebellar cortex of Cal-
bindin 28K positive Purkinje cells (Fig 8c). The nature of enzymes labeled with Anybody addi-
tionally to GBA is not yet fully clear. Aside from GBA, GBA2 and GBA3 also label with β-
aziridine cyclophellitol ABPs [17], and currently labeling of other enzymes cannot be
completely excluded. Of note, prominent presence of GBA2 in Purkinje cells of mice has
indeed been demonstrated by antibody analysis (Fig 8d).
Discussion
So far, no methods exist for visualizing active GBAmolecules in the intact brain. We earlier
developed β-glucopyranosyl-configured cyclophellitol-epoxide ABPs specifically labeling active
GBA in intact cells and viscera of mice [21]. In this study we firstly demonstrate that i.c.v.
administration of such ABPs can be used to detect with high spatial resolution active GBAmole-
cules in the brain. Our findings regarding the distribution of active GBAmolecules in the brain
deserve discussion in view of the documented association of impaired GBA and α-synucleino-
pathies [5–14]. We observed with our ABP-based labeling method that the basal ganglia struc-
tures like the SN, GP andMGN, and brainstem structures like Po, SP5 and Lrt present high
levels of active GBA. These particular structures are involved in motor function and form part
containing microglia cells. (D) SN of i.c.v. infused rats with MDW933. From left to right images of DAPI, green MDW933, red Iba1 antibody and overlay image.
The overlay shows MDW933 signal in areas containing microglia cells. (E) 63x confocal images of the SN and ME of i.c.v. infused rats with MDW933. The
images show from left to right green MDW933 and red NeuN antibody (SN); green Inhibody and red GFAP antibody (ME); green Inhibody and red CD11b
antibody (SN); green Inhibody and red Iba1 antibody (SN).
doi:10.1371/journal.pone.0138107.g005
Fig 6. GBA in sorted CD11b positive microglia and GLT1 positive astrocyte populations. (A) RT PCRmRNA expression of CD11b positive sorted cells.
(B) RT PCRmRNA expression of GLT1 positive sorted cells. (C). Quantification of green MDW933-labeled GBA in microglia and astrocytes expressed per
number of cells.
doi:10.1371/journal.pone.0138107.g006
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of the extrapyramidal system of motor coordination. Our finding of relative high amounts of
active GBA in these motor related areas in the healthy brain may point to an important local
role for the enzyme, consistent with the susceptibility of such areas to develop Lewy Bodies dur-
ing partial GBA deficiency in GD carriers and patients [8]. Various hypotheses have been put
forward to link glucocerebrosidase abnormalities to α-synuclein accumulation. For example, it
has been proposed that the enzyme directly interacts with α-synuclein [32, 33] and mutant
enzyme has been found to be present in Lewy bodies [34]. In addition, it has been proposed that
increased α-synuclein disrupts intracellular trafficking of GBA resulting in a positive feedback
loop amplifying the pathologic effects of α-synuclein [12]. A different hypothesis proposes dis-
turbance of proteasome function following ER-associated degradation of mutant enzyme [35].
Of interest, other brain areas found to be rich in active GBA are the hypothalamus and cin-
gulate cortex. This finding was confirmed by analysis of GBA in dissected areas of brain.
Recently metabolism of ceramide and glucosylceramide in the hypothalamus has been
Fig 7. In vitro labeling of GBA2 in specific brain areas. (A) SDS-PAGE gel of Anybody MDW1044 labeled rat brains areas. (B) Quantification of Anybody
MDW1044 fluorescent signal per μg of protein. (C) GBA2 enzymatic activity in different brain areas. (D) GBA2 protein levels in homogenates of rat brain
areas assessed byWestern blot analysis. (E) Quantification of GBA2 blot in rat brain areas normalized to the same tubulin signal showed in Fig 3e. Note:
cerebellum indicates other parts of cerebellum than cerebellar cortex.
doi:10.1371/journal.pone.0138107.g007
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proposed to play an important role in control of energy homeostasis [36–38]. The prominent
ABP-labeling of active GBA in the hypothalamus is in line with these observations and future
studies with i.c.v. administrations of fluorescent ABPs may shed light on the role of hypotha-
lamic GBA in the regulation of energy homeostasis.
Fig 8. Labeling of cerebellar cortex with β-aziridine cyclophellitol ABP JJB75. (A) Zoom (3x) of 63x confocal images of the cerebellar cortex of green
Inhibody MDW933 > red Anybody JJB75 i.c.v. infused animals. From left to right images of DAPI, green MDW933 signal, and red JJB75 signal are shown.
The overlay shows that Inhibody and Anybody signals colocalize to only a minor extent. (B) Zoom (3x) of 63x confocal image. Cerebellar Cortex of CBE > red
Anybody JJB75 i.c.v. infused animals. From left to right images of DAPI, red JJB75, anti-GBA2 antibody signal (green) and overlay image are shown. (C)
Zoom (3x) of 63x confocal images of the cerebellar cortex of Inhibody MDW933 > Anybody JJB75 i.c.v. infused animals. From left to right images of DAPI,
green MDW933, red JJB75, Calbindin 28K antibody staining (magenta) and overlay image are shown. (D) GBA2 presence in Purkinje cells in mouse brain.
From left to right: HE staining, Calbindin 28K antibody staining and anti-GBA2 antibody staining in separate sections.
doi:10.1371/journal.pone.0138107.g008
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Conceivable is future use of the here-described procedure for in vivo labeling of GBA in
brain to investigate the effects of pharmacological agents. The efficacy of agents aiming to
increase GBA levels in the brain can be studied using saturating ABP labeling. In theory, one
could attempt to analyze the interaction of pharmacological agents with the GBA catalytic
pocket by demonstrating competitive inhibition of ABP labeling. For this purpose, conditions
would first need to be carefully established at which ABP labeling is not yet saturating.
A discussion of our findings in view of neuropathic GD is warranted. In the neuropathic
variants of Gaucher disease neuronal accumulation of glucosylceramide occurs. The relation
between lipid accumulation and neuropathology is still not completely understood. Recent
studies with mouse models have led to interesting novel insights. Firstly, studies by Futerman
and colleagues revealed that neuronal loss induced by exposure of mice to CBE, a brain-perme-
able suicide inhibitor of GBA, stems not from apoptosis but rather necrosis mediated by
RIP3K [39]. Recently, the same research group also studied GBA-deficient neuropathic
Gaucher disease (nGD) mice on the relationship between neuropathology and accumulation of
glucosylceramide and glucosylsphingosine, the deacylated form of the lipid [40]. Four distinct
areas were dissected from brains: the cortex and the ventral posteromedial/posterolateral
(VPM/VPL) region of the thalamus (areas displaying significant pathology), and the caudate
putamen (CPu) and the periaqueductal gray (PAG) (areas not displaying pathology). Interest-
ingly, no strict correlation between GlcCer accumulation and residual GBA activity, as mea-
sured in vitro, was noted. GlcCer was found to accumulate comparably in the various brain
regions, preceding accumulation of glucosylsphingosine. Only glucosylceramide accumulation
was found to correlate with neuroinflammation and neuron loss. It was concluded that in the
nGD mouse model a certain level of neuronal glucosylceramide storage is required to trigger
neuropathological changes in affected brain areas, while other brain areas containing similar
glucosylceramide levels are unaltered. Our analysis of the distribution of active GBA molecules
across the healthy rodent brain does also not point to a simple match of GBA abundance in
brain with the noted neuropathology in nGD mice. Areas like the cortex and thalamus display-
ing prominent pathology in nGDmice do not show an exceptional content on active GBA mol-
ecules in normal rat brain. It is attractive to conclude, similar to Futerman and colleagues [40]
that beyond the primary GBA defect intrinsic differences in neuronal properties or in the neu-
ronal environment between various brain regions determine onset of GD neuropathology. One
such modulating factor could be the second glucocerebrosidase GBA2 [41,42]. Prominent ABP
labeling of GBA2, confirmed by antibody staining, is seen for the cerebellar cortex, specifically
in Purkinje neurons. Recent reports have indicated a clear association between GBA2 muta-
tions and the development of cerebellar disorders and motor neuron neurodegeneration
[43,44]. Our investigation revealed that in normal rat brain Purkinje cells in the cerebellar cor-
tex present the highest GBA2. Of interest, also the thalamus appears rich in GBA2. In fact, the
brain distribution of GBA2, being prominent in cortex and also rich in the thalamus, mimics
more closely the areas involved in neuropathology in nGD mice as that of GBA.
Our novel method of ABP-based labeling of glucocerebrosidase in the brain offered also
some insight in the types of cells expressing high levels of active GBA molecules in vivo. We
observed that especially neurons present high amounts of active GBA. Labeling of active GBA
in astrocytes and microglia is less pronounced. Astrocytes and microglia populations isolated
from forebrain and hindbrain structures were examined ex vivo on GBA content. Astrocytes
were found to have higher GBA activity than microglia, especially in the case of forebrain struc-
tures. Of interest, astrocytes are known to also develop Lewy Bodies [45]. Somewhat surprising
is the observation of a relative low content of GBA in isolated microglia. Neuroinflammation
and the presence of activated microglia in the areas with major neuronal cell death are thought
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to be major factors promoting neuronal cell death in alpha-synucleinopathies and neurono-
pathic GD mouse models [46,47].
In conclusion, when infused i.c.v., fluorescent β-glucopyranosyl cyclophellitol-epoxide
ABPs can visualize active GBA molecules in the brain and thus help to increase insight in the
role of this enzyme in neurodegenerative disorders. The β-glucopyranosyl cyclophellitol-aziri-
dine type ABPs label next to GBA also other glycosidases like GBA2 and can be used to estab-
lish the distribution of active molecules of various enzymes along the brain. The relative high
expression of GBA and GBA2 in neuronal cells in specific motor areas of the brain seems to
correlate with motor related neurological disorders associated with their deficiencies such as
Parkinson disease and cerebellar ataxia, respectively.
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